APM
ESPR icon

Avidity Partners Management’s Esperion Therapeutics ESPR Stock Holding History

Avidity Partners Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400,000
Closed -$8.46M – 117
2021
Q2 		$8.46M Buy
+400,000
New +$9.63M 0.23% 77
2020
Q3 		– Sell
-559,700
Closed -$28.7M – 76
2020
Q2 		$28.7M Buy
559,700
+354,700
+173% +$14.8M 1.84% 19
2020
Q1 		$6.46M Buy
205,000
+74,600
+57% +$3.94M 0.89% 43
2019
Q4 		$7.78M Buy
+130,400
New +$5.86M 4.9% 7

Other funds holding ESPR

Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Avidity Partners Management's ESPR Position: Q3 2021 in Review

Avidity Partners Management sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 400,000 shares — an estimated $8.46M sold.

Avidity Partners Management first reported a position in ESPR in Q4 2019 and held it in 4 quarters. The position peaked at $28.7M in Q2 2020. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

  • Avidity Partners Management reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Avidity Partners Management sold 400,000 Esperion Therapeutics shares in Q3 2021, an estimated $8.46M.
  • Avidity Partners Management first reported a position in Esperion Therapeutics in Q4 2019 and held it in 4 quarters.
  • Avidity Partners Management's Esperion Therapeutics position peaked at $28.7M in Q2 2020.
  • 139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.